Investigators from the Mass General Brigham Cancer Institute have found that adults with newly diagnosed acute myeloid leukemia (AML) receiving a less-intensive combination of azacitidine and venetoclax had more than twice as much time before treatment failed, the leukemia returned or worsened, or they died, compared with patients receiving intensive chemotherapy. Published in the New England Journal of Medicine, the findings could change the initial treatment approach for many patients with AML.
from Medical Xpress - latest medical and health news stories https://ift.tt/I0auXiN
